Abous Us

Corporate profile

Grünenthal is a global leader in pain management and related disease.

We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercialisation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards, and we focus our efforts on our vision of a World Free of Pain.

Grünenthal at a glance
Our virtual company showcase provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.
Enter
keywords
Strong and capable team
4,400

employees worldwide

Solid revenue base
1.8

billion euros in 2023

Commercial presence in
27

countries across Europe, Latin America, and the US

Products sold in around
100

countries

International network
2

R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)

Production capacities
5

manufacturing sites in Europe and Latin America

Contract Manufacturing GRT PRO

Global capabilities

Although firmly rooted in Germany, today we are very much a growing global business: since spreading our wings beyond Germany in the 1960s, we have continued to grow steadily and expand our market presence and product portfolio. We collaborate with commercial partners and multiple stakeholders from the pain management field and beyond in order to make our medicines available to patients.

Explore our global presence and sites
Pipeline

Pipeline

To move closer to our vision of a world free of pain, we are currently pursuing a range of programs across different modalities, targets, and mechanisms of action. Here are some selected highlights from our development pipeline: RTX (resiniferatoxin), MPC-06-ID, Glucocorticoid Receptor Modulator (GRM), Nociceptin/Orphanin FQ receptor Peptide agonist (NOP).

Explore Grünenthal's development pipeline